UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstracts for References 2,3,56,57,68,70,78,85,86

of 'Chemotherapy-induced alopecia'

2
TI
A practitioner's guide to cancer-related alopecia.
AU
Dorr VJ
SO
Semin Oncol. 1998;25(5):562.
 
Alopecia due to the side effects of the treatment of cancer is one of the most common and emotionally troublesome effects of cancer therapy. Preventive measures, primarily scalp hypothermia, can be effective in some cases, but the worry of subsequent scalp metastasis remains. Investigative studies in animals are hindered by a poor animal alopecia model. Several promising agents require translation into clinical practice. Until then, disguising the alopecia with wigs, hats, or turbans remains the mainstay of treatment.
AD
Ellis Fischel Cancer Center, University of Missouri, Columbia 65203, USA.
PMID
3
TI
Chemotherapy-induced alopecia: new developments.
AU
Hussein AM
SO
South Med J. 1993;86(5):489.
 
Alopecia (hair loss) is one of the most physically and psychologically distressing side effects of cancer chemotherapeutic drugs. Since its first recognition as a common outcome to most chemotherapeutic agents, only a few trials have been reported, using either a method to temporarily reduce the scalp blood flow (scalp tourniquet or hypothermia) or vitamin E, with undocumented and variable efficacy. The lack of progress in the treatment and prevention of chemotherapy-induced alopecia is in part due to the lack of a reproducible animal model. In the past 2 years, we reported on the following observations: (1) treatment of 8-day-old rats with vidarabine (ara-C), doxorubicin, and cyclophosphamide consistently produced either total body alopecia (ara-C and cyclophosphamide) or alopecia confined to the head and proximal part of the back (doxorubicin); (2) Imuvert, a biologic response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against alopecia induced by ara-C and doxorubicin but not that produced by cyclophosphamide; (3) the protective effect of Imuvert against chemotherapy-induced alopecia is mediated by a monocyte-mediated cytokine; and (4) this monocyte-derived cytokine is, possibly, interleukin-1. These observations constitute important progress in the understanding and prevention of chemotherapy-induced alopecia.
AD
William J. Harrington Center for Blood Diseases, University of Miami School of Medicine, Fla.
PMID
56
TI
Scalp hypothermia in the prevention of chemotherapy-induced alopecia.
AU
Vendelbo Johansen L
SO
Acta Radiol Oncol. 1985;24(2):113.
 
Alopecia is a common side effect of cancer chemotherapy, especially in combination with regimens with doxorubicin (Adriamycin). The effect of scalp hypothermia in connection with chemotherapy was evaluated as hair protection in 61 women with disseminated breast carcinoma, where earlier treatment routines had caused wig-requiring alopecia in nearly all patients. The cooling was performed with a gel-helmet (Hypotherm Gel-Kap). Of the 61 patients, 47 (77%) had no or slight, not wig-demanding hair loss, and 14 (23%) had severe (wig-demanding) hair loss. Seven patients had liver dysfunction; in 5 of these severe hair loss was observed; 2 had slight hair loss. Eighty-three per cent of the patients with normal liver function had no hair loss. Treatment tolerance was found to be good, and side effects were minimal. The method is found to be simple, effective and inexpensive, though still not technically optimal.
AD
PMID
57
TI
Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer.
AU
Tollenaar RA, Liefers GJ, Repelaer van Driel OJ, van de Velde CJ
SO
Eur J Cancer. 1994;30A(10):1448.
 
35 patients were studied to determine the effectiveness of scalp hypothermia in the prevention of alopecia caused by adjuvant chemotherapy for breast cancer. Scalp hypothermia was induced by the newly developed Theracool cooling machine. The chemotherapeutic regimen consisted of one perioperative course of doxorubicin 50 mg/m2, cyclophosphamide 600 mg/m2 and 5-fluorouracil 600 mg/m2 (EORTC protocol 10854). Only 4 (11%) patients showed acceptable hair preservation (no or minor alopecia). 12 patients (34%) had moderate alopecia, all requiring a wig. 19 patients (54%) had complete alopecia. No scalp metastases were observed after scalp cooling. These results and a review of the literature suggest that scalp hypothermia to prevent alopecia may only be effective in a cytotoxic regimen containing an anthracycline as the sole alopecia-inducing agent. With current adjuvant chemotherapy for breast cancer, in which a combination of cyclophosphamide and an anthracycline is often used, there is no place for scalp hypothermia.
AD
Department of Surgery, University Hospital Leiden, The Netherlands.
PMID
68
TI
The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss.
AU
Satterwhite B, Zimm S
SO
Cancer. 1984;54(1):34.
 
A randomized clinical trial was performed to determine the effectiveness of scalp hypothermia in the prevention of hair loss associated with doxorubicin. Twenty-six patients were randomized to receive scalp hypothermia or chemotherapy alone. Data were analyzed on 25 patients: 12 in the treatment group and 13 in the control group. There was acceptable hair preservation in 75% of the patients who received the scalp hypothermia; only 8% of the patients in the control group had acceptable hair preservation (P = 0.0009). The data were further broken down into patients receiving low-dose doxorubicin and high-dose doxorubicin. Side effects were minimal. The results support the use of scalp hypothermia in reducing doxorubicin-induced alopecia.
AD
PMID
70
TI
Scalp hypothermia in the prevention of doxorubicin-induced hair loss.
AU
Giaccone G, Di Giulio F, Morandini MP, Calciati A
SO
Cancer Nurs. 1988;11(3):170.
 
AD
PMID
78
TI
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
AU
Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J
SO
Eur J Cancer. 1997;33(2):297.
 
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m2 docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia<or = 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them; 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients.
AD
Centre Oscar Lambret, Lille, France.
PMID
85
TI
Misuse of scalp hypothermia.
AU
Witman G, Cadman E, Chen M
SO
Cancer Treat Rep. 1981;65(5-6):507.
 
Scalp hypothermia has been introduced to reduce the temporary epilation associated with certain cytotoxic drugs. This has improved compliance with drug delivery for some patients. It is currently not recommended for use in those tumors with a high prevalence of scalp metastasis, ie, leukemia and lymphoma. We have treated a patient for mycosis fungoides who demanded use of a "cooling cap" while undergoing consolidation chemotherapy. Cutaneous disease recurred on the scalp, with no other evidence of mycosis fungoides. Caution should be used in reducing drug delivery to the scalp while treating tumors manifesting cutaneous stem cell tumor nests.
AD
PMID
86
TI
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
AU
Rugo HS, Melin SA, Voigt J
SO
Breast Cancer Res Treat. 2017;163(2):199. Epub 2017 Mar 8.
 
PURPOSE: The risk of scalp metastases in patients using scalp cooling for preservation of hair during chemotherapy has been a concern but is poorly described.
METHODS: A systematic review and meta-analysis of longitudinal studies was undertaken to evaluate the effect of scalp cooling versus no scalp cooling on the risk of scalp metastasis in patients treated for breast cancer with chemotherapy. Electronic databases, journal specific, and hand searches of articles identified were searched. Patients were matched based on disease, treatment, lack of metastatic disease, and sex.
RESULTS: A total of 24 full-text articles were identified for review. Of these articles, ten quantified the incidence of scalp metastasis with scalp cooling over time. For scalp cooling, 1959 patients were evaluated over an estimated mean time frame of 43.1 months. For no scalp cooling, 1238 patients were evaluated over an estimated mean time frame of 87.4 months. The incidence rate of scalp metastasis in the scalp coolinggroup versus the no scalp cooling group was 0.61% (95% CI 0.32-1.1%) versus 0.41% (95% CI 0.13-0.94%); P = 0.43.
CONCLUSION: The incidence of scalp metastases was low regardless of scalp cooling. This analysis suggests that scalp cooling does not increase the incidence of scalp metastases.
AD
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF Medical Center at Mount Zion, 1600 Divisadero St, San Francisco, CA, 94115, USA.
PMID